Curis, Inc. (NASDAQ:CRIS) has earned an average rating of “Hold” from the six analysts that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $6.50.
Separately, Zacks Investment Research upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 8th.
Curis (NASDAQ:CRIS) traded up $0.04 during trading on Wednesday, reaching $0.52. 1,579,642 shares of the company’s stock were exchanged, compared to its average volume of 1,390,000. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.24. Curis has a 52 week low of $0.47 and a 52 week high of $3.22. The firm has a market cap of $93.37, a P/E ratio of -1.34 and a beta of 1.68.
Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its position in shares of Curis by 62,201.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock valued at $3,691,000 after acquiring an additional 2,377,975 shares during the period. Vanguard Group Inc. raised its position in shares of Curis by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 4,955,068 shares of the biotechnology company’s stock valued at $9,365,000 after acquiring an additional 127,443 shares during the period. State Street Corp raised its position in shares of Curis by 10.4% in the 2nd quarter. State Street Corp now owns 1,857,044 shares of the biotechnology company’s stock valued at $3,511,000 after acquiring an additional 175,424 shares during the period. First Eagle Investment Management LLC raised its position in shares of Curis by 10.4% in the 3rd quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after acquiring an additional 2,500,000 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of Curis by 1.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 1,880 shares during the period. Institutional investors and hedge funds own 46.27% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/03/03/curis-inc-cris-receives-6-50-consensus-target-price-from-analysts.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.